Iterum Therapeutics Announces Major PBM Agreement for ORLYNVAH(TM)

Iterum Therapeutics has finalized a commercial contract with a Group Purchasing Organization that collaborates with a major Pharmacy Benefit Manager in the US. The contract adds coverage opportunities for over 24 million lives starting in early 2026, accelerating market access for its antibiotic, ORLYNVAH™. This milestone underscores the growing acceptance of ORLYNVAH™ across the payor landscape.